In vivo, D-2HG and L-2HG differentially altered ILC subset distribution across mucosal and lymphoid compartments.<h4>Conclusions</h4>IDH1 mutations and their associated oncometabolite D-2HG remodel the innate lymphoid cell landscape in gliomas, driving an ILC3-biased phenotype with reduced checkpoint receptor expression. This evidence concerns the gene IDH1 and central nervous system cancer.